Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company described as a global leader in minimally invasive treatments for lung disease, with a focus on chronic obstructive pulmonary disease (COPD) and severe emphysema. The LUNG news page on Stock Titan aggregates company press releases and market updates so readers can follow how Pulmonx’s business and capital markets profile evolve over time.
News about Pulmonx often centers on financial results, including quarterly revenue, gross margin, operating expenses, net loss, and non-GAAP metrics such as Adjusted EBITDA and constant currency revenue growth. Earnings releases also discuss revenue trends between the United States and international markets, reflecting adoption of Zephyr Valve procedures and related technologies in more than 25 countries.
Another recurring theme in Pulmonx news is clinical and commercial progress for the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports. The company highlights the Zephyr Valve’s FDA pre-market approval following its designation as a “breakthrough device,” its inclusion in global treatment guidelines, and its role as a standard of care option for certain severe emphysema patients.
Investors and observers will also find corporate governance and leadership updates reported through press releases and corresponding Form 8-K filings, such as the reappointment of Glen French as President and Chief Executive Officer and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer. Additional news items cover participation in healthcare and growth investor conferences, where management presents Pulmonx’s story to the investment community.
By reviewing the LUNG news feed, readers can track Pulmonx’s reported financial performance, executive transitions, equity inducement grants, and investor outreach activities, all of which provide context for understanding the company’s progress in the COPD and emphysema treatment market.
Pulmonx Corporation (LUNG) reported strong financial results for Q4 and full year 2021, with Q4 revenue reaching $13.7 million (+39%) and full-year revenue at $48.4 million (+48%). The company achieved a gross margin of 74.8% in Q4, up from 72.0% in 2020. Operating expenses increased by 38% to $22.6 million in Q4, leading to a net loss of $13.0 million. For 2022, Pulmonx forecasts revenues between $55 million and $60 million, despite ongoing COVID-19 impacts.
Pulmonx Corporation (Nasdaq: LUNG) announced its participation in the Citi 2022 Virtual Healthcare Conference on February 24, 2022, at 8:45 AM PT / 11:45 AM ET. The event will feature a fireside chat with the company's leaders discussing their innovative treatments for severe lung disease. A live and archived webcast will be available on the Investors section of Pulmonx's website. Pulmonx specializes in minimally invasive solutions, notably the Zephyr® Endobronchial Valve, which has been approved by the FDA and is available in over 25 countries, treating more than 25,000 patients.
Pulmonx Corporation (Nasdaq: LUNG) will release its financial results for Q4 and full year 2021 on February 23, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET for discussion and analysis of the results. Investors can participate via phone or through a live webcast available on Pulmonx's investor website. Pulmonx is recognized for its minimally invasive solutions for severe lung disease, including the Zephyr® Endobronchial Valve, which has treated over 25,000 patients globally.
Pulmonx Corporation (Nasdaq: LUNG) has announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 7:30 a.m. EST. The presentation will be accessible via a live and archived webcast on the company’s investors webpage.
Pulmonx is recognized for its innovative solutions for severe lung disease, notably the Zephyr® Endobronchial Valve, which has received FDA pre-market approval. The valve is currently available in over 25 countries, having been used in more than 25,000 patients worldwide.
Pulmonx Corporation (Nasdaq: LUNG) will participate in the 33rd Annual Piper Sandler Healthcare Conference from November 29 to December 2, 2021. The management team will hold investor meetings on December 1, 2021, and a pre-recorded fireside chat will be available on the company’s website starting November 22, 2021. Pulmonx is recognized for its minimally invasive treatments for severe lung disease, including the Zephyr® Endobronchial Valve, which has been used in over 100,000 procedures worldwide. For more information, visit Pulmonx Investors.
Pulmonx Corporation (Nasdaq: LUNG) announced its participation in two virtual investor conferences. Management will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 12:20 PM PT / 3:20 PM ET, available via webcast on their website. Additionally, they will attend investor meetings at the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum on November 18, 2021. Pulmonx specializes in minimally invasive treatments for severe lung diseases, including emphysema and COPD, with over 100,000 Zephyr Valves used globally.
Pulmonx Corporation (LUNG) reported a 25% increase in worldwide revenue for Q3 2021, totaling $13.3 million, compared to $10.6 million in Q3 2020. The gross margin improved to 73% from 70% year-over-year. U.S. revenue rose 28% to $6.9 million. Operating expenses surged 52% to $19.5 million, leading to a net loss of $10.2 million or $0.28 per share. Pulmonx maintains its full-year revenue guidance of $49 to $51 million, amid ongoing COVID-19 uncertainties.
Pulmonx Corporation (Nasdaq: LUNG) will release its third quarter 2021 financial results on November 2, 2021, post-market. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Investors can join the call by dialing (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 9545716. Pulmonx is known for its minimally invasive treatments for lung diseases, including the Zephyr® Endobronchial Valve, which has been used in over 25,000 patients worldwide.
Pulmonx Corporation (NASDAQ: LUNG) announced that Blue Cross Blue Shield of Michigan and Horizon BCBS of New Jersey have issued positive coverage policies for the Zephyr® Endobronchial Valve, a treatment for severe emphysema. This gives access to nearly 10 million covered lives, adding to existing BCBS coverage for 69 million members. The Zephyr Valve is minimally invasive and improves lung function without the risks of major surgery. More than 25,000 patients have been treated with the valve globally, with significant clinical backing.
Pulmonx Corporation (Nasdaq: LUNG) announced its participation in two virtual investor conferences. Management will engage in fireside chats at the 2021 Virtual Wells Fargo Healthcare Conference on September 9, 2021, at 7:00 AM PT and the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 1:15 PM PT. Interested parties can access live and archived webcasts on the Pulmonx website. Pulmonx is known for its minimally invasive treatments for severe lung diseases, including the Zephyr Endobronchial Valve, which has received FDA approval and is available in over 25 countries.